Crossmark

Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial

Crossref DOI link: https://doi.org/10.1186/s12885-022-09802-y

Published Online: 2022-07-01

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fu, Wei-Jun

Wang, Ya-Fei

Zhao, Hong-Guo

Niu, Ting

Fang, Bai-Jun

Liao, Ai-Jun

Bai, Hai

Lu, Jin
License Information

Text and Data Mining valid from 2022-07-01

Version of Record valid from 2022-07-01
More Information

Article History

Received: 16 December 2021

Accepted: 16 June 2022

First Online: 1 July 2022

Declarations

:

: This study was approved by the ethics committee of each participating institution as follows: Ethics Committee of Changzheng Hospital, The Second Military Medical University; Ethics Committee of Tianjin Medical University Cancer Institute and Hospital; Ethics Committee of The Affiliated Hospital of Qingdao University; Ethics Committee of West China Hospital, Sichuan University; Ethics Committee of Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital; Ethics Committee of Shengjing Hospital of China Medical University; Ethics Committee of General Hospital of Lanzhou Military Region of the PLA; Ethics Committee of Peking University People's Hospital. The study was conducted in accordance with the Declaration of Helsinki. All study subjects provided written informed consent prior to enrollment.

: Not applicable (this manuscript does not contain information or photographs that potentially lead to the identity of any study participant).

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below